CDK4 and oligodendroglioma: Overall, the efficacy data from this trial suggest that further studies are needed to identify the subgroup(s) of patients with oligodendroglioma who may have tumors sensitive to CDK4/6 inhibition, and that novel therapeutic combinations incorporating CDK4/6 inhibition should be considered for preclinical and eventual clinical evaluation in this disease.